Back to Search
Start Over
[JMJD3 Exerts Oncorepressor Activity in Acute Promyelocytic Leukemia by Promoting PU.1 Expression].
- Source :
-
Molekuliarnaia biologiia [Mol Biol (Mosk)] 2023 Jul-Aug; Vol. 57 (4), pp. 665-667. - Publication Year :
- 2023
-
Abstract
- All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) has been the most famous differentiation induction therapy during which the expression of PU.1, a key transcription factor (TF) for myeloid lineage determination in normal hematopoiesis is restored. In our previous studies, we found a stress-inducible H3K27 demethylase, JMJD3, to directly upregulate PU.1 expression to promote myeloid commitment during normal myelopoiesis. In addition, JMJD3 acts as an oncorepressor and plays a critical regulatory role in the initiation and progression of malignant hematopoiesis. In this study, we further resolved the relationship between JMJD3 and PU.1 in APL therein JMJD3 exerts oncorepressor activity via promoting PU.1 expression.
- Subjects :
- Humans
Trans-Activators genetics
Proto-Oncogene Proteins genetics
Proto-Oncogene Proteins metabolism
Tretinoin pharmacology
Tretinoin therapeutic use
Transcription Factors genetics
Cell Differentiation
Leukemia, Promyelocytic, Acute drug therapy
Leukemia, Promyelocytic, Acute genetics
Leukemia, Promyelocytic, Acute metabolism
Subjects
Details
- Language :
- Russian
- ISSN :
- 0026-8984
- Volume :
- 57
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Molekuliarnaia biologiia
- Publication Type :
- Academic Journal
- Accession number :
- 37528785
- Full Text :
- https://doi.org/10.31857/S0026898423040213, EDN: QMAEUQ